Sujets)
Humains , Femelle , Adulte , Transplantation d'organe/effets indésirables , Rejet du greffon/traitement médicamenteux , Immunosuppresseurs/analyse , Immunosuppresseurs/pharmacologie , Azathioprine/usage thérapeutique , Tacrolimus/antagonistes et inhibiteurs , Ciclosporine/antagonistes et inhibiteurs , Hormones corticosurrénaliennes/administration et posologie , Sirolimus/antagonistes et inhibiteurs , Inhibiteurs de la calcineurine/usage thérapeutique , Évérolimus/antagonistes et inhibiteurs , Acide mycophénolique/usage thérapeutiqueRésumé
Cyclosporin A (CsA)-induced hyperkalemia is caused by alterations in transepithelial K(+) secretion resulting from the inhibition of renal tubular Na(+), K(+) -ATPase activity. Thyroxine enhances renal cortical Na(+), K(+) -ATPase activity. This study investigated the effect of thyroxine on CsA-induced hyperkalemia. Sprague-Dawley rats were treated with either CsA, thyroxine, CsA and thyroxine, or olive-oil vehicle. CsA resulted in an increase in BUN and serum K(+), along with a decrease in creatinine clearance, fractional excretion of potassium, and renal cortical Na(+), K(+) -ATPase activity, as compared with oil vehicle administration. Histochemical study showed reduced Na(+), K(+) -ATPase activity in the proximal tubular epithelial cells of the CsA-treated compared with the oil-treated rats. Histologically, isometric intracytoplasmic vacuolation, disruption of the arrangement and swelling of the mitochondria, and a large number of lysosomes in the tubular epithelium were characteristic of the CsA-treated rats. Co-administration of thyroxine prevented CsA-induced hyperkalemia and reduced creatinine clearance, Na(+), K(+) -ATPase activity, and severity of the histologic changes in the renal tubular cells when compared with the CsA-treated rats. Thyroxine increased the fractional excretion of potassium via the preservation of Na(+), K(+) -ATPase activity in the renal tubular cells. Thus, the beneficial effects of thyroxine may be suited to treatment modalities for CsA-induced hyperkalemia.
Sujets)
Animaux , Mâle , Rats , Ciclosporine/antagonistes et inhibiteurs , Hyperkaliémie/induit chimiquement , Immunosuppresseurs/antagonistes et inhibiteurs , Cortex rénal/effets des médicaments et des substances chimiques , Microsomes/enzymologie , Potassium/sang , Rat Sprague-Dawley , Sodium-Potassium-Exchanging ATPase/métabolisme , Thyroxine/pharmacologieRésumé
Effect of unique hemorrheologic agent pentoxifylline (PTX) was investigated on cyclosporine (CsA) induced nephrotoxicity in rats. Compared to saline control, CsA produced significant increase in blood urea and serum creatinine. Pentoxifylline treatment prevented the CsA-induced rise in blood urea and serum creatinine. Creatinine clearance (Ccr) and lithium clearance (Licr) was decreased with CsA. PTX treatment prevented the CsA-induced decrease in Ccr and Licr. Malondialdehyde (MDA) was increased with CsA compared to saline treated animals. PTX prevented the CsA-induced MDA rise. Kidney form CsA treated rat showed marked vacuolar degeneration of tubular epithelium with excess of microcalcification. Severity of the lesions was markedly reduced in rats treated with PTX plus CsA. The results indicate that PTX reduces CsA-induced renal toxicity in rats.